These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

66 related articles for article (PubMed ID: 7335926)

  • 1. [Optimal posology in the neoplastic treatment (author's transl)].
    Periti P
    Radiol Med; 1981; 67(7-8):537-49. PubMed ID: 7335926
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The interval between courses of high-dose chemotherapy with stem cell rescue: therapeutic hypotheses.
    Frei E; Richardson P; Avigan D; Bunnell C; Wheeler C; Elias A
    Bone Marrow Transplant; 1999 Nov; 24(9):939-45. PubMed ID: 10556951
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The dynamics of cell proliferation.
    Moxnes JF; Haux J; Hausken K
    Med Hypotheses; 2004; 62(4):556-63. PubMed ID: 15050107
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Modeling of the time-dependency of in vitro drug cytotoxicity and resistance.
    Levasseur LM; Slocum HK; Rustum YM; Greco WR
    Cancer Res; 1998 Dec; 58(24):5749-61. PubMed ID: 9865733
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evolving concepts in the systemic drug therapy of breast cancer.
    Norton L
    Semin Oncol; 1997 Aug; 24(4 Suppl 10):S10-3-S10-10. PubMed ID: 9275000
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anticancer Drug Development: The Way Forward.
    Connors T
    Oncologist; 1996; 1(3):180-181. PubMed ID: 10387985
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modeling oxaliplatin drug delivery to circadian rhythms in drug metabolism and host tolerance.
    Clairambault J
    Adv Drug Deliv Rev; 2007 Aug; 59(9-10):1054-68. PubMed ID: 17707544
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Dose intensity in cancer chemotherapy: definition, average relative dose intensity and effective dose intensity].
    Alberto P
    Bull Cancer; 1995; 82 Suppl 1():3s-8s. PubMed ID: 7626852
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Distributed parameters deterministic model for treatment of brain tumors using Galerkin finite element method.
    Chakrabarty SP; Hanson FB
    Math Biosci; 2009 Jun; 219(2):129-41. PubMed ID: 19345698
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dynamics of the biological response to molecular injury: a mathematical model.
    Periti P; Capelo A; Comincioli V
    Farmaco Sci; 1980 Sep; 35(9):752-62. PubMed ID: 7450056
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cancer immunotherapy, mathematical modeling and optimal control.
    Castiglione F; Piccoli B
    J Theor Biol; 2007 Aug; 247(4):723-32. PubMed ID: 17543345
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dose and schedule as determinants of outcomes in chemotherapy for breast cancer.
    Budman DR
    Semin Oncol; 2004 Dec; 31(6 Suppl 15):3-9. PubMed ID: 15726532
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mathematical modelling for the assessment of the effect of drug application delays in metronomic chemotherapy of cancer due to physiological constraints.
    Mukherjee A; Majumder D
    Biosystems; 2008 Jan; 91(1):108-16. PubMed ID: 17889991
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic drug monitoring of cancer chemotherapy.
    Alnaim L
    J Oncol Pharm Pract; 2007 Dec; 13(4):207-21. PubMed ID: 18045780
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone).
    Pergolizzi J; Böger RH; Budd K; Dahan A; Erdine S; Hans G; Kress HG; Langford R; Likar R; Raffa RB; Sacerdote P
    Pain Pract; 2008; 8(4):287-313. PubMed ID: 18503626
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Optimal controls for a model with pharmacokinetics maximizing bone marrow in cancer chemotherapy.
    Ledzewicz U; Schättler H
    Math Biosci; 2007 Apr; 206(2):320-42. PubMed ID: 16197967
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oral paclitaxel and concurrent cyclosporin A: targeting clinically relevant systemic exposure to paclitaxel.
    Britten CD; Baker SD; Denis LJ; Johnson T; Drengler R; Siu LL; Duchin K; Kuhn J; Rowinsky EK
    Clin Cancer Res; 2000 Sep; 6(9):3459-68. PubMed ID: 10999729
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [General principles of dose-effect relationship].
    Borg C; Trillet-Lenoir V
    Bull Cancer; 2001 Sep; 88(9):833-4. PubMed ID: 11604354
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Optimal control oriented to therapy for a free-boundary tumor growth model.
    Calzada MC; Fernández-Cara E; Marín M
    J Theor Biol; 2013 May; 325():1-11. PubMed ID: 23485361
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Optimal control of treatment in a mathematical model of chronic myelogenous leukemia.
    Nanda S; Moore H; Lenhart S
    Math Biosci; 2007 Nov; 210(1):143-56. PubMed ID: 17599363
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.